Vouched and Verisart Partner to Provide Peace of Mind for NFT Artists, Investors
Power to the Beeple, and to every other artist, collector, and investor working to expand the boundaries of fine art by bringing works tied to nonfungible tokens (NFTs) to the mainstream.
Vouched and Verisart today announced an industry-first partnership to apply Vouched’s unique digital identity verification technology to Verisart’s first-of-its-kind blockchain certification platform for digital artists and collectors. The partnership is a significant step forward for the NFT art industry, which has recently seen spikes in interest after a piece created by artist Beeple sold for $69.3 million, a new record for purely digital work.
“The rise of NFTs demonstrates that virtually everything in our known history can be adapted to a digital future, from healthcare to banking to real estate, and now fine art,” said John Baird, Co-Founder, and CEO of Vouched. “Identity verification is absolutely foundational to every element of this ongoing digital revolution. We are excited to work with Verisart to bring Vouched’s unmatched AI technology to the world of NFT art, helping to unleash creativity for artists and enable more confident investing for collectors.”
Vouched’s identity verification platform will be used as part of Verisart’s new patent-pending global standard for digital art certification, enabling creators, collectors, and dealers to easily create digital certificates registered on the blockchain.
“While there may be a lot of hype around the NFT art market right now, it highlights an important advancement that is here to stay and will continue to reshape how we create, authenticate and value those creations moving forward,” said Robert Norton, CEO of Verisart. “Verisart is pioneering the capability to apply blockchain to certification in the art and collectibles market. We support creativity by facilitating trusted transactions and empowering artists to establish their careers and legacies, regardless of what their works sell for.”
Starting immediately, artists can create secure certificates of authenticity for their NFTs on Verisart using Vouched’s platform by using their ID and Vouched’s facial recognition tools to ensure they are who they say they are. The same process is being utilized for collectors on Verisart to verify purchaser identity, creating an extra layer of security for both the artist and the buyer.
About Vouched
Vouched is proprietary artificial intelligence and computer vision that powers end-to-end visual identity verification and fraud detection online in real-time. An expert on more than 450 government-issued identity documents, including driver’s licenses, passports, and permanent resident cards, in 50+ countries, Vouched helps banks, gig and sharing companies, and hospital and healthcare providers verify and onboard users to provide access to life’s most critical services instantly.
For more information on Vouched, visit www.vouched.id, or contact Vouched communications at 1-800-674-8798 or press@vouched.id.
About Verisart
Verisart is an award-winning certification service enabling artists, galleries, and collectors to create certificates of authenticity securely registered on the blockchain. Founded in 2015 as the first company to apply blockchain to certification in the art and collectibles market, Verisart has pioneered a new patent-pending global standard for certification. Over 20,000 artworks have been certified on the platform by more than 5000 artists including Shepard Fairey, Ai Weiwei, Jules De Balincourt, Penny Slinger, and Derek Boshier.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210413005446/en/
Contact information
Danny Kerth
Danny.Kerth@fleishman.com
314.570.0090
Janna Nallet
janna@consortpartners.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CORRECTING and REPLACING PHOTO Decode the Future of AI and Customer Experience at Elevate'25 Digital Innovation Summit18.9.2025 21:23:00 EEST | Press release
Please replace the photo with the accompanying corrected photo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918928987/en/ Gain insight and advice from firms at the frontier of AI-powered, mobile-first customer experiences. The release reads: DECODE THE FUTURE OF AI AND CUSTOMER EXPERIENCE AT ELEVATE'25 DIGITAL INNOVATION SUMMIT With keynotes from Google Cloud and an independent research firm, Elevate’25 will provide actionable strategies to harness the power of AI and create exceptional experiences for today's mobile-first consumer As unprecedented advancements in AI reshape consumer behavior, digital innovation summit Elevate'25 opened for general registration today. Sponsored by Airship, the exclusive, one-day event is designed to equip business leaders with proven strategies to harness artificial intelligence and mobile-first technology for a decisive competitive advantage. Taking place on October 15, 2025, at the i
Sai Life Sciences Opens Dedicated Facility for Veterinary APIs in Bidar, India18.9.2025 19:22:00 EEST | Press release
Sai Life Sciences (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the opening of Unit VI, a dedicated facility for Veterinary Active Pharmaceutical Ingredient (API) production, in Bidar, India. Located alongside Unit IV, the company’s flagship API manufacturing site, Unit VI has been established exclusively for veterinary APIs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918612071/en/ Sai Life Sciences’ Veterinary APIs Unit in Bidar, India. The new facility is designed to meet the highest standards of safety, sustainability, and regulatory compliance, ensuring the production of high-quality APIs for veterinary applications. With this expansion, Sai Life Sciences aims to provide efficient and scalable manufacturing solutions to leading global animal health companies. Making the announcement, Krishna Kanumuri, CEO & Managing Direct
Celltrion Announces Commercial Availability of Omlyclo™ Across Europe at EADV 202518.9.2025 18:45:00 EEST | Press release
Celltrion, Inc. today showcased its longstanding commitment to expanding its biosimilar portfolio in the field of immuno-dermatology by attending the 2025 European Academy of Dermatology and Venereology (EADV) Congress, held 17-20 September in Paris, France. Following the European Commission (EC) approval of Omlyclo™, the first and only omalizumab biosimilar in Europe in May 2024, Omlyclo™ will be commercially available starting in Norway, with subsequent rollouts in European countries. As part of Celltrion’s mission to advance knowledge and understanding in dermatology, especially in chronic spontaneous urticaria (CSU), the company hosted satellite symposium presenting the results of the global Phase III clinical trial of Omlyclo™. The global Phase III clinical trial involved 619 patients with CSU, following them up to week 40. Patients were randomized to receive 300 mg or 150 mg of Omlyclo™, or reference product, every 4 weeks. Starting from week 12, patients who received Omlyclo™ we
Setting the Standard: AMRA Medical Recognized as one of TIME Magazine’s ‘World’s Top HealthTech Companies’18.9.2025 17:40:00 EEST | Press release
AMRA Medical is proud to share its inclusion in the World’s Top HealthTech Companies list, published today by TIME in collaboration with Statista. This recognition positions AMRA among an elite group of global innovators that are leading healthcare transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918372780/en/ AMRA Medical Recognized as one of TIME Magazine’s ‘World’s Top HealthTech Companies’ The selection, which comes just one week after celebrating AMRA’s 15 years of progress and innovation within the body composition space, highlights AMRA’s long-standing commitment to becoming a global leader in health informatics. By delivering detailed, reproducible insights within fat distribution and muscle composition, AMRA’s MRI-based technology is helping clinicians, researchers, and healthcare organizations unlock new levels of understanding across the metabolic and musculoskeletal sectors. “Being recognized by
illumynt, a CNE Direct Company, Is Pleased to Announce the Promotion of Jörg Herbarth to Chief Executive Officer (CEO)18.9.2025 17:30:00 EEST | Press release
illumynt, a CNE Direct company, is pleased to announce the promotion of Jörg Herbarth to Chief Executive Officer (CEO). Jörg has been a key member of illumynt’s executive leadership team since joining in June 2022, most recently serving as Chief Operating Officer. In his new role as CEO, Jörg will spearhead illumynt’s mission to become the number one provider of AI- and data-centric IT Asset Disposition (ITAD) solutions worldwide. Paul Knight, illumynt’s current CEO, will transition to the role of Founder & Chairman. In this capacity, Paul will continue to support the executive team with strategic guidance, while Jörg assumes full leadership of day-to-day operations and global expansion initiatives. Mr. Knight had come out of retirement a year ago to undertake some new initiatives and advance the company's strategic direction. With some necessary changes having taken place- he is thrilled to facilitate this transition to a reduced role again. Under Jörg’s leadership, illumynt will cont
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom